A Study of RBT-1 in Healthy Volunteers and Subjects With Stage 3/4 Chronic Kidney Disease

NCT ID: NCT03893799

Last Updated: 2025-08-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 54 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-08-27
• Study Completion Date: 2020-12-31

Brief Summary

This is a Phase 1b, single-center, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effect of RBT-1 in healthy volunteers and in subjects with Stage 3/4 CKD.

Conditions

Healthy Volunteers; Chronic Kidney Disease

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

9 mg SnPP/240 mg FeS

Group Type: EXPERIMENTAL

RBT-1

Intervention Type: DRUG

Single intravenous administration

27 mg SnPP/240 mg FeS

Group Type: EXPERIMENTAL

RBT-1

Intervention Type: DRUG

Single intravenous administration

45 mg SnPP/240 mg FeS

Group Type: EXPERIMENTAL

RBT-1

Intervention Type: DRUG

Single intravenous administration

63 mg SnPP/240 mg FeS

Group Type: EXPERIMENTAL

RBT-1

Intervention Type: DRUG

Single intravenous administration

90 mg SnPP/240 mg FeS

Group Type: EXPERIMENTAL

RBT-1

Intervention Type: DRUG

Single intravenous administration

Interventions

RBT-1

Single intravenous administration

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male and female subjects age 18 to 80 years (inclusive, at time of ICF).

2. Body weight <125 kg.

3. Able and willing to comply with all study procedures.

4. Female subjects must be either post-menopausal for at least 1 year or surgically sterile (tubal ligation, hysterectomy or bilateral oophorectomy) for at least 3 months, or if of childbearing potential, have a negative pregnancy test and agree to use dual methods of contraception, or abstain from sexual activity from Screening until 28 days after study drug administration.

Male subjects with female partners of childbearing potential must agree to use a highly effective method of contraception from screening until 28 days after study drug administration. All fertile men with female partners of childbearing potential should be instructed to contact the Investigator immediately if they suspect their partner might be pregnant (e.g., missed or late menstrual period) at any time during study participation.

5. CKD Stage 3 as determined by estimated glomerular filtration rate (eGFR) between 30-59 mL/min/1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

6. CKD Stage 4 as determined by eGFR between 15-29 mL/min/1.73 m2 using the CKD-EPI equation.

Exclusion Criteria

1. History of malignancy except carcinoma in situ in the cervix, early stage prostate cancer or non-melanoma skin cancers.

2. Use of investigational drugs or participation in another clinical trial within 30 days or 5 half-lives prior to screening, whichever is longer.

3. Serum ferritin > 500 ng/ml or who have received IV iron within 28 days of screening, or currently being treated with oral iron.

4. Women who are pregnant, breastfeeding, or planning to become pregnant while participating in the study.

5. Any significant acute or chronic diseases.

6. Subjects with abnormal baseline liver tests or hepatitis serologies that suggest active infection.

7. Regular use of drugs of abuse and/or positive findings on urinary drug screening.

8. Current tobacco use and/or positive findings on urinary cotinine screening.

9. Subjects who are severely physically or mentally incapacitated and who, in the opinion of investigator, are unable to perform the subjects' tasks associated with the protocol.

10. Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated.

11. Subjects with history of photosensitivity or active skin disease

12. Known hypersensitivity or previous anaphylaxis to RBT-1 or to components thereof.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Renibus Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Riverside Clinical Research

Edgewater, Florida, United States

Countries

United States

References

Zager RA, Johnson ACM, Guillem A, Keyser J, Singh B. A Pharmacologic "Stress Test" for Assessing Select Antioxidant Defenses in Patients with CKD. Clin J Am Soc Nephrol. 2020 May 7;15(5):633-642. doi: 10.2215/CJN.15951219. Epub 2020 Apr 14.

Reference Type: DERIVED

PMID: 32291269 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

REN-001A

Identifier Type: -

Identifier Source: org_study_id